

JOURNEES DE PHYSIOLOGIE EN CARDIOLOGIE INTERVENTIONNELLE

### INOQUOI ?

Pr Gilles Barone-Rochette Interventional cardiology and cardiac imaging Pôle Thorax et vaisseaux- CHU de Grenoble

Inserm 1039



#### HÔTEL SHERATON · NICE



### Disclosure

- Consulting: Abbott Vascular, Bayer, Novonordisk, General electric, Medis imaging
- Honoraria: Bayer, AMGEN, Sanofi, AstraZeneca, Novonordisk, Novartis, Pfizer, Boehringer Ingelheim
- Grants: MDS, Pfizer, Bayer, Abbott vascular



INOCA: Ischemia with Non Obstructive Coronary Artery disease

# ANOCA: angina with no obstructive coronary artery disease







- Is it serious?
- How common is it?
- Assessment and treatment





### Pronostic

11 223 patients referred for coronary angiography with stable angina pectoris as indication and 5705 participants from the Copenhagen City Heart Study for comparison





HÔTEL SHERATON · NICE

Jespersen et a. lEuropean Heart Journal (2012) 33, 734–744.

5@6 AVRIL 2024

### Pronostic





Perf: 0:N

HÔTEL SHERATON · NICE

2:Abnormal 3:Severe 4:Absent





Sinha et al. European Heart Journal (2021) 42, 4431-4441





### Two compartment model



Maitre-Ballesteros L,..., Barone-Rochette G. Rev. Cardiovasc. Med. 2022; 23(5): 158



## Functional aspects of the coronary microcirculation





5**&6 AVRIL 2024** 

Herrmann et al. European Heart Journal (2012) 33, 2771–2781

HÔTEL SHERATON · NICE



### **Microvascular Dysfunction**



(Physioday

5&6 AVRIL 2024 HÔTEL SHERATON · NICE



At least 10% to 40% of patients presenting with angina have no significant CAD on invasive coronary angiography.

As many as **50% to 70%** of these patients with chest pain without obstructive CAD are believed to have coronary microvascular dysfunction



Marinescu et al. J Am Coll Cardiol Img 2015;8:210–20



#### Modalities to assess coronary microvascular function



PHYSIODAY

5&6 AVRIL 2024 HÔTEL SHERAT<u>ON · NICE</u>

### **Recommendations ESC 2019**

#### Investigations in patients with suspected coronary microvascular angina

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Guidewire-based CFR and/or microcirculatory resistance measurements should be consid- ered in patients with persistent symptoms, but coronary arteries that are either angiographi- cally normal or have moderate stenoses with preserved iwFR/FFR. <sup>412,413</sup>	lla	в
Intracoronary acetylcholine with ECG moni- toring may be considered during angiography, if coronary arteries are either angiographically normal or have moderate stenoses with pre- served iwFR/FFR, to assess microvascular vasospasm. <sup>412,438–440</sup>	IIb	В
Transthoracic Doppler of the LAD, CMR, and PET may be considered for non-invasive assessment of CFR. <sup>430–432,441</sup>	Ш	в

PHYSIODAY

### **Recommendations AHA 2021**







SPECIAL ARTICLE Coronary artery disease

An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group

Non-invasive functional techniques are options to detect ischaemia in INOCA.

ETT, TTDE, MCE, SPECT MRI, PET

Currently, no technique allows a direct anatomical visualization of the coronary microcirculation *in vivo* in humans. Therefore, its assessment relies on the measurement of parameters which reflect its functional status, such as myocardial blood flow and CFR.



Physioday





Figure 1. LEFT, short axis (SA), horizontal long axis (HLA) and vertical long axis (VLA) views and bull's eye from SPECT MPI indicated severe apical hypoperfusion (arrows) (summed stress score [SSS], 7; summed rest score [SRS], 0). Coronary angiography (CA) of the left anterior descending artery revealed the absence of obstructive CAD, a normal FFR value (0.99; normal FFR values, > 0.8), an elevated IMR (30, normal IMR values, < 23), and the alteration of coronary flow reserve (CFR) (1.1; normal CFR values, > 2).

Loic Djaileb,..., Gilles Barone-Rochette et al. J Nucl Cardiol 2017



ANOCA/ INOCA





Ford et al. J Am Coll Cardiol Intv 2020;13:33–45

FIGURE 2 Primary Efficacy Endpoint: Quality of Life Mean Scores at Baseline and at 6 and 12 Months

Ford et al. J Am Coll Cardiol 2018;72:2841–55

(PHIYSIO DAY

5&6 AVRIL 2024 HÔTEL SHERATON · NICE



- INOCA and ANOCA are frequent in cath lab
- Microcirculation dysfunction must be explored in ANOCA and INOCA patients to improve their symptoms and quality of life.
- Possible impact on MACE : science is in progress



